Novartis Stops Late-Stage Trial of Remibrutinib for Lack of Efficacy
Novartis said it stopped a late-stage trial of remibrutinib in a rare neuromuscular disease due to lack of efficacy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.